We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

bioMérieux

Designs, develops, manufactures and markets in vitro diagnostics systems used in clinical and industrial applications read more Featured Products: More products

Download Mobile App




Novel Flu Test Developed to Speed Up Treatment

By LabMedica International staff writers
Posted on 20 Apr 2017
A novel way of using a swab test has been developed which can rapidly diagnose influenza and other viral infections in patients with severe respiratory conditions, resulting in shorter courses of antibiotics and less time in hospital.

Rapid point-of-care testing (POCT) for respiratory viruses might improve clinical care by reducing unnecessary antibiotic use, shortening length of hospital stay, improving influenza detection and treatment, and rationalizing isolation facility use; however, insufficient evidence exists to support its use over standard clinical care.

Doctors and their colleagues at University Hospital Southampton enrolled adults, aged equal to or over 18 years within 24 hours of presenting to the emergency department or acute medical unit of a large UK hospital with acute respiratory illness or fever higher than 37.5 °C for less than seven days duration, or both, over two winter seasons. More...
Patients were randomly assigned (1:1), via an internet-based allocation sequence with random permuted blocks, to have a molecular POCT for respiratory viruses or routine clinical care.

Of the 301 (84%) of 360 patients in the POCT group received antibiotics compared with 294 (83%) of 354 controls and mean duration of antibiotics did not differ between groups (7·2 ± 5.1 days). The investigators found that 50/301(17%) of patients treated with antibiotics in the POCT group received single doses or brief courses of antibiotics (less than 48 hours) compared with 26 (9%) of 294 patients in the control group. Mean length of stay was shorter in the POCT group (5.7 ± 6·3 days) than in the control group (6·8 ± 7.7 days).

The authors concluded that patients who had the point-of-care test got the right treatment for their lung condition faster. In addition, patients who tested positive for influenza in the point-of-care testing group were appropriately isolated in a side room and given antiviral medication more often and sooner than those in the standard care group.

Tristan W Clark, MD, an associate professor in infectious diseases and senior author of the study, said, “My vision is that anyone who comes into hospital with an acute respiratory condition will receive this point-of-care test as soon as they come through the hospital door. It tells us immediately what virus the person has so, for example, if they have influenza they can be isolated in a side room and given antiviral drugs without delay.” The study was published on April 6, 2017, in the journal Lancet Respiratory Medicine.


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
Multichem ID-B
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.